Smoking Relapse Prevention Among COPD Ex-smokers — SPACE  

Chronic Obstructive Pulmonary Disease Clinical Trial

Official title: Smoking Relapse Prevention Among COPD Ex-smokers

Status Terminated

Clinical Trial Summary

A placebo-controlled trial to determine whether recent ex-smokers with COPD who successfully stop smoking after taking varenicline are less likely to relapse back to smoking if they continue using varenicline for a further 12 weeks

Clinical Trial Description

Smoking remains the leading cause of Chronic Obstructive Pulmonary Disease (COPD), a leading cause of death and disability in New Zealand. COPD particularly affects indigenous Māori and Pacific people, given their higher rates of smoking. COPD patients tend to have a higher level of nicotine dependence and, as a result, often find quitting harder and are more likely to relapse back to smoking. A clinical trial (N=262) is planned in Auckland, New Zealand to determine whether extended varenicline treatment combined with behavioural support can prevent relapse back to smoking in recent ex-smokers with COPD. Smoking cessation and relapse prevention are the most cost-effective interventions available for COPD patients that smoke, irrespective of their disease stage. The trial has the potential to significantly improve the outcomes of this common and chronic health condition in New Zealand. ;

Related Conditions & MeSH terms

• Chronic Obstructive Pulmonary Disease
• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive
• Smoking Cessation

• NCT number: NCT02888444
• Study type: Interventional
• Source: University of Auckland, New Zealand
• Status: Terminated
• Phase: Phase 3
• Start date: July 31, 2017
• Completion date: April 13, 2018